After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Relying on a single strand of hair, LinusBio is launching its diagnostic aid for autism spectrum disorder—with a test ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations.

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...